CCR5 and breast cancer: Pervaiz et al. has demonstrated that blocking CCR5 with MVC reduces the proliferation and migration of metastatic breast cancer, and the drug significantly inhibited BC (MDA-MB-231) bone metastasis in nude mice [224].